Preliminary Clinical Observations on the Treatment of 20 Cases of Severe Immune-Mediated Diseases Using the Combined Immune-Inflammation Adsorption System (CIAS)

Wei Zhang, Xiaohui Yan

Show Less

¹ Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi, China,

JCNR 2026 , 10(5), 77–83; https://doi.org/10.26689/jcnr.v10i5.15220

© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To investigate the short-term efficacy and safety of the Combined Immune-Inflammation Adsorption System (CIAS) in the treatment of severe immune-mediated diseases. Methods: A retrospective analysis was conducted on the clinical data of 20 patients with severe immune-mediated diseases treated at our hospital using CIAS, which involved a series connection of the Kangbail® Protein A Immunoadsorption Column and the Kangseitong® Hemoperfusion Device. Changes in key laboratory indicators and clinical symptoms before and after treatment were compared. Results: A total of 68 treatment sessions were completed across the 20 patients. The mean reduction in IgG levels after a single treatment was (46.2 ± 11.3)% (p < 0.01). In patients with lupus nephritis, anti-ds-DNA antibody titers decreased by (68.4 ± 15.2)%, and 24-hour urine protein levels decreased from (4.8 ± 2.1) g/day to (1.2 ± 0.7) g/day (p < 0.01); Antibody levels in patients with anti-glomerular basement membrane disease decreased significantly, with 3 cases (75%) becoming independent of dialysis; in the group of highly sensitized patients prior to kidney transplantation, the positive rate of reactive antibodies (PRA) decreased from (76.5 ± 18.3)% to (21.4 ± 12.6)% (p < 0.01), and all patients successfully underwent transplantation. Post-treatment, both IL-6 and TNF-α levels decreased by more than 50% (p < 0.05). The overall clinical remission rate was 85% (17/20), including 6/7 cases of lupus nephritis, 3/4 cases of anti-GBM disease, 3/4 cases of ANCA-associated vasculitis, and 5/5 cases of highly sensitized pre-transplant patients. The incidence of treatment-related adverse reactions was 14.7% (10/68 sessions), primarily consisting of mild hypotension, bleeding at the puncture site, and mild allergic reactions. All symptoms resolved after symptomatic treatment, and no serious complications occurred. Conclusion: CIAS demonstrates definite short-term efficacy in severe immune-mediated diseases, with good safety and manageable adverse reactions, and can serve as a rescue treatment option for patients who have not responded well to conventional drug therapy.

References

Ding Y, Yang Z, Zhang L, et al., 2026, Clinical Analysis of the Combined Use of Immunosuppressants and Glucocorticoids in the Treatment of Severe Pneumonia Complicating Pediatric Immune-Mediated Kidney Diseases. Journal of Rare and Rare Diseases, 33(03): 138–141.

Alnaimat F, AbuHelal A, Elmusa R, et al., 2026, Immune Rehabilitation After Renal Transplantation in Autoimmune Diseases: Balancing Immunosuppression and Risk of Complications. Autoimmunity Reviews, 25(4): 104031.

Zhang L, Guo Y, Huang H, et al., 2025, The Role of Continuous Blood Purification Techniques in the Treatment of Patients with Acute Kidney Injury Due to Sepsis. China Medical Device Information, 31(17): 144–146.

Chen M, Wu G, Niu H, et al., 2025, A Study on the Role and Mechanism of Hemoperfusion for Inflammatory Adsorption in the Treatment of Sepsis-Induced Cardiomyopathy. Journal of Lingnan Emergency Medicine, 30(06): 636–639.

Zheng N, An Z, Liu H, et al., 2019, Effects of Uridqing Granules Combined with Combined Artificial Kidney on Lipid Metabolism, Inflammatory Response, and Cellular Immune Function in Patients with Diabetic Nephropathy Undergoing Maintenance Hemodialysis. Journal of Modern Integrated Traditional and Western Medicine, 28(20): 2208–2211.

Cheng J, 2025, Establishment of an Evaluation System for the Efficacy of Integrated Traditional Chinese and Western Medicine in Lupus Nephritis, thesis, Yunnan University of Traditional Chinese Medicine.

Zhao Y, Gao Y, Zhu R, et al., 2025, A Case of Anti-GBM Disease Complicated by IgA Nephropathy. Zhejiang Clinical Medicine, 27(12): 1873–1875.

Kaur M, Chittipolu S, Marathi R, et al., 2026, A Rare Diagnostic Crossroad: ANCA Vasculitis with C3 Glomerulopathy. The American Journal of the Medical Sciences, 371(Suppl 1): S94–S95.

Chen Q, Yan Z, Liu L, et al., 2026, Analysis of the Efficacy of Rituximab Combined with Mycophenolate Mofetil in the Treatment of Lupus Nephritis. Chinese Journal of Modern Drug Application, 20(09): 82–85.

Zeng Y, Hou C, Wu W, et al., 2025, Analysis of the Efficacy of Immunoadsorption in the Treatment of Pediatric Neuroimmunological Diseases. Chinese Journal of Neuroimmunology and Neurology, 32(04): 307–312.

Previous article in this issue

Next article in this issue